<DOC>
	<DOCNO>NCT01216124</DOCNO>
	<brief_summary>The 10 % -15 % breast carcinoma know 'triple negative ( TN ) ' ( express HRs exhibit overexpression Her2 ) constitute 85 % basal-like tumor , base three standard immunohistochemical biomarkers . In clinical routine , Docetaxel widely indicate first-line therapy breast cancer patient adjuvant neoadjuvant setting . Oxaliplatin , trans-1-diaminocyclohexane-platinum , may offer advantage platinum agent . Oxaliplatin promote formation DNA adduct , prevent DNA replication transcription ultimately cause apoptosis . Oxaliplatin potent cisplatin Oxaliplatin-based regimen active patient lung cancer , colorectal cancer ect . TNBC patient sensitive platinum-based chemotherapy regimen accord result retrospective study . There report Oxaliplatin chemotherapy set breast cancer patient . The investigator hypothesize use Oxaliplatin add docetaxel would feasible active patient TNLABC vitro finding suggest synergism agent . This study design investigate efficacy toxicity oxaliplatin-based regimen neoadjuvant chemotherapy set triple negative local advance breast cancer patient</brief_summary>
	<brief_title>Efficacy Safety Study Neoadjuvant Chemotherapy Local Advanced Triple Negative Breast Cancer Patients</brief_title>
	<detailed_description>Eligibilty Female adult ( &gt; 18 year old ) eligible histologically cytologically confirm stage IIIb IIIc TNLABC treat systemic treatment . Patients also Eastern Cooperative Oncology Group ( ECOG ) Performance status 0 1 , absolute neutrophil count ( ANC ) &gt; 1500/mm3 , hemoglobin &gt; 8.0g/dL , platelet count &gt; 100,000/mm3 , creatinine &lt; 2.5 time upper limit normal ( ULN ) ） , transaminases &lt; 2.5 time ULN alkaline phosphatase &lt; 4 time ULN transaminase normal , total bilirubin &lt; 2.5 time ULN . Exclusion criterion active infection , pregnancy , primary malignancy ( except situ carcinoma cervix adequately treat nonmelanomatous carcinoma skin ) , document distant metastasis uncontrolled systemic disease . This study protocol approve institutional ethic review board conduct accord guideline good clinical practice Helsinki Declaration.All patient provide write informed consent . Study design treatment plan This prospective , open unicentric phase II clinical study . All chemotherpy administer intravenously outpatient basis . The patient receive dexamethasone 7.5mg orally twice day 3 day day chemotherapy . On day 1 , docetaxel 75mg/m2 infused 60 minute well oxaliplatin 130mg/m2 infuse 120 minute day 2 . Thirty minute chemotherapy , premedication consist 5-hydroxytryptamine3 ( HT3 ) receptor antagonist . Furthermore , Vitamin C 2g Vitamin B2 200mg follow immediately chemotherapy . Treatment administer every 21 day maximum four cycle disease progression unacceptable toxicity.The prophylactic use colony-stimulating factor ( CFS ) permit first cycle . An initial diagnosis unilateral primary breast cancer without distant metastasis , least 7 month follow-up information disease recurrence death triple receptor negative estrogen receptor ( ER ) , progesterone receptor ( PR ) , Her2 include pre-treatment evaluation . Moreover tumor size , number involve axillary lymph node ( ALN ) , clinical stage biomarkers Cathepsin-D , P53 , nm23 , PS2 PCNA , record available information analysis . In procedure neoadjuvant chemotherapy , weekly biweekly complete blood cell count , physical examination , electrocardiogram ( EKG ) , liver rental function test repeat . Tumor size assess magnetic resonance imaging ( MRI ) every two cycle clinical sign suggest disease progression well chemotherapy . Tumor response determine response evaluation criterion solid tumor ( RECIST ) . Complete partial response ( CR PR ) confirm two assessment perform least four week apart .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>1 . Women age 18 65 year ; 2 . Histologically cytologically proven invasive unilateral breast cancer ( regardless type ) ; 3 . Initial clinical condition compatible complete initial resection ; 4 . No residual macro microscopic tumor surgical excision ; 5 . Patient present one follow criterion ( review randomization referent pathologist ) : Triple Negative ( ERPRHer2 ) Hormone receptor negativity define ER &lt; 10 % , PR &lt; 10 % ( IHC ) , HER2 negativity define IHC 01+ , [ IHC 2+ FISH CISH negative ] . 6 . No clinically radiologically detectable metastasis ( M0 ) ; 7 . No peripheral neuropathy &gt; 1 ; 8. WHO Performance status ( ECOG ) 0 1 ; 9 . Adequate hematological function ( neutrophil count ³ 2x109/l , platelet count ³ 100x 109/l , Hemoglobin &gt; 9 g/dl ) ; 10 . Adequate hepatic function : ASAT ALAT £ 1.5 ULN alkaline phosphatases £ 2.5 ULN , total bilirubin £ 1,5 ULN ; 11 . Adequate renal function : serum creatinine £ 1.5 ULN ; 12 . Patients accept contraception intake overall length treatment childbearing potential ; 13 . Adequate cardiac function , LEVF value &gt; 50 % Muga scan echocardiography ; 14 . Signed write informed consent . 1 . Bilateral breast cancer patient controlateral DCIS ; 2 . Any metastatic impairment , include homolateral subclavicular node involvement , regardless type ; 3 . Any tumor ³ T4a ( UICC1987 ) ( cutaneous invasion , deep adherence , inflammatory breast cancer ) ; 4 . Luminal A , Luminal B Her2 overexpression 5 . Any clinically radiologically suspect nonexplored damage controlateral breast ; 6 . Previous cancer ( except cutaneous basocellular epithelioma uterine peripheral epithelioma ) precede 5 year , include invasive controlateral breast cancer ; 7 . Patients already include another therapeutic trial involve experimental drug ; 8 . Patients concurrent severe and/or uncontrolled medical disease infection could compromise participation study ; 9 . LEVF &lt; 50 % ( MUGA scan echocardiography ) ; 10 . Clinically significant cardiovascular disease ( e.g . unstable angina , congestive heart failure , uncontrolled hypertension ( &gt; 150/90 ) , myocardial infarction cerebral vascular accident ) within 6 month prior randomization ; 11 . Known prior severe hypersensitivity reaction agent study 12 . Women childbearing potential unwilling unable use acceptable method avoid pregnancy entire study period 8 week treatment completion ; 14 ) Women pregnant breastfeeding . Adequate birth control measure take study treatment phase ; 15 ) Women positive pregnancy test en enrollment prior study drug administration ; 16 ) Patients psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial ; 17 ) Individual deprive liberty place authority tutor .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>triple negative local advance breast cancer ( TNLABC ) , neoadjuvant chemotherapy</keyword>
</DOC>